Abstract
Dihydropyrimidine dehydrogenase (DPD) is the principal enzyme involved in the catabolism of 5 fluorouracil (5 FU). The clinical importance of DPD has recently been demonstrated wit the identification of rare cases presenting a severe toxicity to 5 FU related to proven DPD deficiency. We report a new case in a patient with concurrent congenital osteogenesis imperfecta. We were surprised to find another similar association reported by Lyss. It is tempting to speculate that DPD activity may be abnormally regulated in osteogenesis imperfecta patients.
Publication types
-
Case Reports
-
English Abstract
-
Review
MeSH terms
-
Anemia, Aplastic / chemically induced
-
Antimetabolites, Antineoplastic / adverse effects*
-
Antimetabolites, Antineoplastic / metabolism
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Breast Neoplasms / complications
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / enzymology
-
Chemotherapy, Adjuvant
-
Cyclophosphamide / administration & dosage
-
Dihydrouracil Dehydrogenase (NADP)
-
Female
-
Fluorouracil / adverse effects*
-
Fluorouracil / metabolism
-
Humans
-
Leukopenia / chemically induced
-
Middle Aged
-
Mitoxantrone / administration & dosage
-
Osteogenesis Imperfecta / complications*
-
Oxidoreductases / deficiency*
-
Thrombocytopenia / chemically induced
Substances
-
Antimetabolites, Antineoplastic
-
Cyclophosphamide
-
Mitoxantrone
-
Oxidoreductases
-
Dihydrouracil Dehydrogenase (NADP)
-
Fluorouracil